Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Crombie

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Blood Advances|August 13, 2021
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L Crombie, Amy C Sherman, Chi-An Cheng, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Open Forum Infectious Diseases|August 31, 2022
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid MalignanciesAmy C Sherman, Jennifer L Crombie, ChiAn Cheng, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Blood Advances|August 13, 2021
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L Crombie, Amy C Sherman, Chi-An Cheng, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Open Forum Infectious Diseases|August 31, 2022
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid MalignanciesAmy C Sherman, Jennifer L Crombie, ChiAn Cheng, et al.
Pageof 6